Upstream Bio (NASDAQ:UPB) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Upstream Bio (NASDAQ:UPB) in a research note released on Tuesday, MarketBeat Ratings reports. The firm issued an overweight rating and a $38.00 price target on the stock.

Other research analysts have also issued research reports about the company. William Blair initiated coverage on Upstream Bio in a research report on Tuesday. They issued an “outperform” rating for the company. TD Cowen assumed coverage on Upstream Bio in a report on Tuesday. They issued a “buy” rating for the company.

Upstream Bio Price Performance

Shares of NASDAQ:UPB opened at $27.02 on Tuesday. Upstream Bio has a 52 week low of $20.74 and a 52 week high of $29.46.

Insider Transactions at Upstream Bio

In other news, major shareholder Ai Upstream Llc acquired 1,175,000 shares of Upstream Bio stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the transaction, the insider now directly owns 1,175,000 shares of the company’s stock, valued at $19,975,000. The acquisition was disclosed in a filing with the SEC, which is available at this link. In other Upstream Bio news, major shareholder Ai Upstream Llc bought 1,175,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares of the company’s stock, valued at approximately $19,975,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Erez Chimovits purchased 825,000 shares of Upstream Bio stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the acquisition, the director now owns 4,554,873 shares of the company’s stock, valued at approximately $77,432,841. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.